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A personal experience with the influence of
diabetes and other factors on the outcome of
infrainguinal bypass grafts for occlusive disease
Norman R. Hertzer, MD,a James F. Bena, MS,b and Mathew T. Karafa, PhD,b Cleveland, Ohio
Objective: To investigate the influence of diabetes mellitus and other factors on the outcome of all infrainguinal bypass
grafts performed for occlusive disease by a single surgeon at a tertiary referral center.
Methods:The series includes 650 operations in 412men and 238womenwithmedian ages of 65 and 69 years, respectively.
Critical ischemia was the indication for most procedures (n 553, 85%), but 97 (15%) were done for claudication alone.
Nearly half (n  312, 48%) of the patients were diabetic, and 195 (30%) required insulin. All-autogenous vein was used
for 389 grafts (60%). Synthetic or composite materials were employed for the remaining 261 grafts, 91 (35%) of which
were entirely above the knee. Perioperative data were recorded contemporaneously and were supplemented by reviewing
558 of the 565 medical records and the Social Security Death Index. Survival, graft patency, and limb salvage were
analyzed using logistic regression, Kaplan-Meier estimates and proportional hazards models.
Results: Diabetics were more likely to have critical preoperative limb ischemia (P < .001), elevated serum creatinine (P 
.003) or a history of previous coronary intervention (P  .015), lower extremity revascularization (P < .001) or minor
amputations (P  .002). The operative mortality rate was 4.8%, and there were 81 graft occlusions (12%) and 49 major
amputations (7.5%) during the index hospital admission. Patency was immediately restored in 46 of the 81 occluded
grafts, but their secondary patency rates were only 62  16% at 1 year and 26  18% at 5 years. Insulin-dependent
diabetes was associated with a higher incidence of early amputation (odds ratio, 2.6; 95% confidence interval [CI],
1.4-4.8; P  .004). Overall survival was 52  4% at 5 years and 25  5% at 10 years, and there were 175 late graft
occlusions (27%), a total of 198 related reoperations and 107 late amputations (16%). The risks for further occlusion
and/or major amputation after three or more graft revisions were 65% and 71%, respectively. Insulin-dependent diabetes
also was associated with higher late mortality (hazard ratio [HR], 1.5; 95% CI, 1.2-1.8; P  .001) and amputation rates
(HR, 1.5; 95% CI, 1.0-2.1; P  .026), but other independent variables like age, elevated serum creatinine, critical
preoperative ischemia, synthetic conduits, and previous ipsilateral bypass had at least as much influence as diabetes on
survival, graft failure or limb loss.
Conclusions:Diabetes was one of several factors influencing survival and limb preservation, but it did not adversely affect
graft patency. The number of graft revisions was an important predictor of further occlusion or amputation. (J Vasc Surg
2007;46:271-9.)More original articles may have been published world-
wide about infrainguinal bypass during the past 30 years
than on any other topic in the field of vascular surgery. The
consensus of this work appears to be that autogenous
conduits are superior to synthetics for bypass grafting be-
low the knee,1-4 that noninvasive surveillance and preemp-
tive intervention for vein graft stenosis enhances patency
rates,5-7 and that reoperations to revise jeopardized grafts
improve limb salvage.8-11 Other issues have not been com-
pletely resolved, however. Is the popliteal artery a privi-
leged site for synthetic grafting above the knee? Is claudi-
cation alone an appropriate indication for surgical
treatment? Should age or gender be considered in the
selection of bypass candidates? What is the outlook for
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thrombosis? Is there a point at which further attempts at
revascularization become futile because of multiple previ-
ous failures? The present report reviews the personal expe-
rience of one of the authors (N.R.H.) with infrainguinal
bypass grafting during 28 years at The Cleveland Clinic,
with emphasis on these questions as well as the influence of
diabetes mellitus and other factors on survival, graft pa-
tency, and major amputation.
MATERIAL AND METHODS
The senior author constructed 650 infrainguinal bypass
grafts in 565 patients with occlusive arterial disease from
July 1976 through December 2002. A nonoperative ap-
proach traditionally was taken for patients having only
moderate claudication,12,13 and, for this reason, critical
ischemia manifest by rest pain, cutaneous ulceration, gan-
grene, and/or distal emboli was the surgical indication for
a consistent majority (n  553, 85%) of operations
throughout the study period. Ninety-seven procedures
(15%) were done for claudication alone.
Demographic information and perioperative complica-
tions were recorded contemporaneously on index cards
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terial was supplemented by reviewing the electronic medi-
cal record and 558 of the 565 conventional charts contain-
ing all hospitalizations and outpatient visits. Additional
information regarding patient survival was obtained from
the Social Security Death Index. The complete dataset then
was entered into Excel software (Microsoft Corporation,
Redmond, Wash) for analysis. The current investigation
was approved by the Cleveland Clinic Institutional Review
Board and complies with the confidentiality requirements
of the Health Insurance Portability and Accountability Act
of 1996.
Patient characteristics. Bilateral infrainguinal bypass
was performed for 85 patients, including 54 (15%) of the
358 men and 31 (15%) of the 207 women. Since it was
possible for certain clinical factors (eg, age, ischemic limb
symptoms, diabetic status, and renal function) in these
patients to differ for each of their bilateral procedures, the
preoperative profile is described in Table I on the basis of
the number of operations. The mean and median ages were
64.2 and 65 years in men compared with 68.2 and 69 years
in women (P .001). Nearly half of the patients (n 312,
48%) were diabetic, and 195 (30%) of them were insulin-
dependent. (Twelve operations were done in 11 patients
whose diabetic status is unknown but arbitrarily has been
classified as nondiabetic.) Diabetics were more likely to
present with critical ischemia (P  .001), elevated serum
creatinine (P. 003) and/or a history of previous coronary
intervention (P  .015), lower extremity revascularization
(P  .001), and toe or forefoot amputations (P .002).
Preoperative cardiac evaluation. Preoperative coro-
nary arteriography was performed prior to 147 infraingui-
nal bypass procedures (23%) beginning in the late 1970s
and eventually was supplemented by noninvasive assess-
ment using either thallium myocardial scanning (n  43,
6.6%) or dobutamine-stress echocardiography (n  45,
6.9%) after these modalities became available in the mid-
1980s and the early 1990s. A comprehensive cardiac eval-
uation was pursued more frequently in patients whose
symptoms were limited to claudication (43/97, 44%) than
in those who needed prompt infrainguinal bypass for criti-
cal ischemia (177/553, 32%; P  .018).
One hundred and twenty-eight operations (20%) were
performed in 114 patients who already had undergone
incidental coronary artery bypass grafting (CABG, n 
102) or percutaneous transluminal coronary angioplasty
(PTCA, n  12) in the past. A small group of 13 patients
received planned preliminary CABG (n  11) or PTCA (n
 2) prior to a total of 14 infrainguinal procedures (2.2%).
The remaining 508 operations (78%) were done in 438
patients who had no history of previous coronary interven-
tion.
Surgical considerations. Table II provides details re-
garding graft material and the outflow target vessels that
were selected for the distal arterial anastomosis. All syn-
thetic and composite grafts were constructed with polytet-
rafluoroethylene (PTFE) and, hereafter, will be considered
together for the purpose of analysis. Forty-one branched orsequential grafts (6.3%) were performed for independent
revascularization of multiple outflow vessels. Diabetics re-
ceived 43 above-knee popliteal grafts (14%), 82 below-
knee popliteal grafts (26%), 165 crural grafts (53%), and 22
grafts to multiple vessels (7.1%). Nondiabetic patients had
63 above-knee popliteal grafts (19%), 117 below-knee pop-
liteal grafts (35%), 139 crural grafts (41%), and 19 grafts to
multiple vessels (5.6%). The common femoral artery was
the inflow source for 575 grafts (88%), but the superficial
femoral artery provided inflow for 37 grafts (5.7%), the
deep femoral artery for 13 (2.0%), and the popliteal artery
for 25 (3.8%).
The methods described by Leather et al14 were em-
ployed during in situ vein grafting, and intravenous infu-
sions of low molecular-weight dextran frequently were
administered for 48 hours postoperatively in patients who
had disadvantaged outflow vessels.15 Intraoperative com-
pletion arteriography was done routinely until approxi-
mately the last 5 years of the study period, when it some-
times was supplanted by Doppler assessment.
Unless there were specific contraindications to its use,
patients who received synthetic grafts below the knee were
considered to be candidates for long-term oral anticoagu-
lation after improved patency rates had been reported with
this approach in 1988.16 Sodium warfarin has been pre-
scribed for 44 (73%) of the 60 patients who were dis-
charged from the hospital with patent synthetic infra-
geniculate grafts since that time, compared with only eight
(9.6%) of 83 similar patients prior to 1988. Daily aspirin
therapy (80 mg to 325 mg) was recommended to all other
patients who had no intolerance to it once the potential
benefit of postoperative platelet inhibition was recognized
in the 1980s.
Follow-up protocol. All patients were encouraged to
return for routine evaluation in 4 to 6 weeks. Objective
follow-up using pulse volume recordings (PVRs) was per-
formed every 6 to 12 months until the mid-1980s, when a
structured time-related protocol for duplex scanning in
addition to PVRs was implemented for autogenous grafts
in response to the common observation that they seemed
most likely to develop new stenotic lesions within the first 2
postoperative years. Patients with vein grafts subsequently
were advised to have noninvasive graft surveillance every 4
months during the first year, every 6 months during the
second year, and annually thereafter. Noninvasive studies
were done for synthetic bypass grafts every 6 months dur-
ing the first 2 years and then on an annual basis.
Statistical analysis. The postoperative and late out-
comes of primary interest were death, graft occlusion, and
major amputation. Associations with these outcomes were
assessed using the following baseline factors: diabetes (no
diabetes vs noninsulin-dependent vs insulin-dependent),
gender, age, preoperative symptoms (claudication alone vs
critical ischemia), serum creatinine, prior CABG or PTCA,
severe clinical chronic obstructive pulmonary disease
(COPD), graft material (all-autogenous vs synthetic/com-
posite), inflow source and outflow target vessel(s), a history
of previous ipsilateral infrainguinal bypass, and the year of
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categorical and continuous factors.
Logistic regression analysis was used to assess univari-
able andmultivariable associations between baseline factors
and postoperative complications, while associations be-
tween baseline factors and late complications were assessed
by Cox proportional hazards regression for both univari-
able and multivariable analyses. Marginal Cox proportional
hazard models17 were used to account for the correlation
between limbs from the same patient, but these results did
not differ greatly from the traditional Cox model. Results
are presented as odds ratios (OR) or hazard ratios (HR) and
95% confidence intervals (CI) with corresponding P values.
Long-term patient survival, graft patency, and limb salvage
rates were calculated using Kaplan-Meier estimates. Eight
patients (1.4%) had no Social Security numbers and were
censored from the survival analyses at the date of their last
known follow-up contact. Data regarding graft complica-
tions were censored at the time of the most recent personal
examination in all patients. Univariable estimates of sur-
vival, patency, and limb salvage (with 95% CI) are reported
at 1, 5, 10, and 15 postoperative years.
Multivariable models for postoperative and late com-
plications were developed considering all variables that
were evaluated univariably, using a forward selection pro-
cedure with a significance criterion of .05. Miscellaneous
assessments were performed using the standard techniques
of 2 analysis for two categorical variables and either a
two-sample t-test or the Wilcoxon rank-sum test, as appro-
priate, when one of the variables was continuous or ordinal,
respectively. Bonferroni correction for multiple compari-
sons was employed for factors having more than two levels.
A significance level of .05 was used for all hypotheses. Data
were analyzed with SAS software, version 9.1 (SAS Insti-
tute Inc, Cary, NC), and are reported according to recom-
mended standards.18
RESULTS
Operative mortality. Early death was attributed to
the infrainguinal bypass procedure if it occurred within 30
days of the operation or if the patient still was confined to
the hospital with postoperative complications for longer
than 30 days. Univariable associations with postoperative
death are shown in Appendix I, online only. The overall
operative mortality rate was 4.8% (31/650) and was 6.7%
(21/312) in diabetics vs 3.0% (10/338) in nondiabetics (P
 .029). Seventeen (55%) of the 31 postoperative deaths
were caused by cardiac events. None of the 13 patients who
received preliminary CABG or PTCA died following in-
frainguinal bypass, but six deaths (4.7%) occurred in con-
junction with the 128 operations in patients who had
undergone incidental CABG or PTCA in the past. There
were 25 deaths (4.9%) after the 508 operations that were
performed in patients who had no history of coronary
intervention (P  .74). As indicated in Table III, the
preoperative serum creatinine (P  .001) and the level of
the outflow target vessel (P  .05) were the only factorsthat were associated with operative mortality rates on mul-
tivariable analysis.
Postoperative complications. Postoperative cardiac
complications occurred after 59 (9.1%) of the 650 proce-
dures (arrhythmia, 3.2%; myocardial infarction, 3.7%; con-
gestive heart failure, 3.7%), pulmonary complications after
seven (1.1%), and renal complications (including transient
contrast-related azotemia) after 19 (2.9%). Myocardial in-
farctions (MIs) were recognized after 21 (4.1%) of the 508
procedures in patients who had no previous coronary inter-
vention, compared with three (2.3%) of the 128 operations
in patients who had a history of incidental CABG or PTCA.
There were no postoperative MIs among the 13 patients
who received planned preliminary CABG or PTCA, but
none of these differences was statistically significant.
Postoperative thrombosis occurred in 44 (11%) of the
389 all-autogenous vein grafts, 27 (12%) of the 222 syn-
thetic grafts, and 10 (26%) of the 39 composite grafts (P
.30). Forty-six of the 56 immediate reoperations success-
fully restored graft patency, but 10 early amputations (18%)
still were necessary in these 56 patients. Seventeen (68%) of
the remaining 25 patients with graft thrombosis had am-
putations when no attempt wasmade to salvage their grafts,
and another 22 patients (3.4%) had amputations in the
absence of graft thrombosis. On multivariable analysis (Ta-
ble III), there were highly significant associations between
a history of previous ipsilateral infrainguinal bypass and
postoperative graft thrombosis (OR, 2.4; 95% CI, 1.4-4.1;
P  .001), and between insulin-dependent diabetes and
amputation (OR, 2.6; 95% CI, 1.4-4.8; P  .004).
Late survival. There have been 406 late deaths involv-
ing 203 (83%) of the 245 diabetics and 193 (67%) of the
289 nondiabetics who survived their initial revasculariza-
tion. The cause of death was documented for 145 of the
406 patients, whereas the other 261 deaths were merely
acknowledged in the medical record or were discovered by
reviewing the Social Security Death Index. Fifty-five (38%)
of the 145 known causes of death were related to fatal
cardiac events.
The median length of follow-up for the survival analysis
was 4.0 years (quartiles, 1.4 and 7.7 years). Of the 565
patients, 448 remained at risk in the survival analysis at 1
year, 238 at 5 years, 97 at 10 years, and 33 at 15 years.
Kaplan-Meier estimates of overall survival rates through 15
years of follow-up are provided in Appendix II, online only,
some of which also are illustrated in Fig 1. Several risk
factors in addition to diabetes had highly significant (P 
.001) univariable associations with long-term mortality,
including older age, elevated serum creatinine, critical pre-
operative ischemia, severe clinical COPD, and a history of
previous ipsilateral infrainguinal bypass. As shown in Table
IV, all of these factors retained their significance on multi-
variable analysis.
Late complications. There have been 332 complica-
tions involving 222 (34%) of the 650 grafts, including
occlusions in 175 (27%, 253 events), stenosis in 61 (9.4%,
64 events), and infections in 15 (2.3%). A total of 198 late
reoperations have been done in 137 grafts (21%), and
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(16%).
Themedian length of follow-up for the analyses of graft
patency and limb salvage was 3.0 years (quartiles, 0.8 and
6.0 years.) Of the 650 bypass grafts, 385 remained at risk in
the analysis of secondary patency at 1 year, 140 at 5 years,
33 at 10 years, and 12 at 15 years. Kaplan-Meier estimates
of late primary patency rates were calculated to include
postoperative graft occlusions and are presented in Appen-
dix III, online only. Secondary patency rates for the 46
grafts in which patency was restored after early postopera-
tive thrombosis were uniformly low at 1 year (62  16% )
and at 5 years (26 18%). Age was the only patient-related
factor that was found to influence primary patency on
multivariable analysis (Table IV), with older age groups
having lower risks for graft occlusion or elective reinterven-
tion than patients who were 59 years of age or younger (P
 .029). Other significant factors included the year of
operation (P  .036), a history of previous ipsilateral
infrainguinal bypass (P  .002), the graft material (P 
.001), and the level of the outflow target vessel (P .014).
Primary patency rates for all-autogenous vein grafts are
compared with those for synthetic or composite grafts
according to outflow vessels in Fig 2. Thirty-two of the 106
above-knee bypass procedures were performed for claudi-
cation alone. The 5-year primary and secondary patency
Fig 1. Kaplan-Meier estimates of survival according to f
diabetes; B, age; C, serum creatinine; and D, preoperati
than 10 patients remained eligible for follow-up.)rates for synthetic femoropopliteal grafts above the kneewere 66  12% and 83  9%, respectively, but so few
above-knee autogenous grafts (n 15) were done that the
absence of a significant difference in patency rates (P .26)
must be interpreted cautiously. Only five of the 91 syn-
thetic above-knee grafts eventually were replaced with dis-
tal grafts using the great saphenous vein. There was no
difference (P .23) in the crude occlusion rates for below-
knee synthetic or composite grafts between patients who
initially were prescribed sodiumwarfarin (22/52, 42%) and
those who were not (48/91, 53%), but patient compliance
and the therapeutic level of oral anticoagulation were not
reliably documented.
All-autogenous grafts had significantly better primary
patency rates than synthetic or composite grafts after be-
low-knee popliteal (P  .020) and crural (P  .001)
procedures (Fig. 2). Nine (19%) of the 47 autogenous
grafts that were constructed strictly for claudication ulti-
mately occluded. The primary, primary assisted, and sec-
ondary patency rates for various types of infrageniculate
vein grafts are presented in Table V. Although others have
reported excellent results using either reversed or in situ
saphenous vein grafts,19,20 in situ grafts were associated
with a substantial advantage in all three patency categories
in the present series. These differences were significant only
for tibial or peroneal bypass, however. Arm vein grafts had
a 5-year primary patency rate that was similar to synthetic or
ighly significant risk factors on multivariable analysis: A,
mptoms. (Dotted lines indicate intervals in which fewerour h
ve sycomposite grafts below the knee, whereas their primary
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20%) were more closely comparable to those for reversed
saphenous grafts. Relatively few operations were done us-
ing transposed non-reversed saphenous grafts (n 13), but
their high primary patency rates remain noteworthy.
Kaplan-Meier estimates of long-term limb salvage rates
were calculated to include postoperative amputations and
are available in Appendix IV, online only. Of the 650 limbs,
393 remained at risk in the analysis of limb salvage at 1 year,
167 at 5 years, 44 at 10 years, and 14 at 15 years. Six major
amputations eventually became necessary after the 97 by-
pass procedures that were done for claudication alone. On
multivariable analysis (Table IV), a higher incidence of
amputation was associated with critical preoperative isch-
emia (P  .001), insulin-dependent diabetes (P  .026),
elevated serum creatinine (P  .005), and the use of
synthetic or composite grafts (P .045). The associations
between these risk factors and limb salvage rates are shown
in Fig 3 for the 553 operations that were performed strictly
for critical ischemia. Amputations were required despite
continuously patent bypass grafts in 23 (18%) of the 125
eligible insulin-dependent diabetics, compared with six
(7.9%) of the 76 noninsulin-dependent diabetics, and 11
(7.1%) of the 154 patients without diabetes (P  .007).
Fig 2. Kaplan-Meier estimates of primary patency acco
grafts compared with synthetic or composite grafts: A,
peroneal; and D, multiple vessels. (Dotted lines indicate
follow-up.)Twenty-nine (72%) of these 40 amputations were belowthe knee, and 23 (58%) were in patients who originally had
presented with established gangrene.
Forty-four (6.8%) of the original 650 grafts in this series
were replaced with entirely new grafts during the study
period. The information in Table VI also incorporates the
results of these replacement grafts and reflects the final
end-of-study outcome for the entire episode of limb revas-
cularization according to several features that conceivably
could influence patient selection for infrainguinal bypass.
These data have been adjusted for length of follow-up and
suggest the following conclusions: (1) gender did not
significantly influence the incidence of occluded grafts or
major amputations; (2) younger patients, diabetics and
patients who had critical preoperative ischemia were more
likely to incur amputations but not necessarily occluded
grafts; (3) a history of previous ipsilateral infrainguinal
bypass failure was associated with a significant chance for
further graft occlusion or amputation; (4) early postopera-
tive thrombosis remained the harbinger for an eventual
occluded graft once initial patency had been restored by
reoperation; and (5) the risk for an occluded graft or
amputation was directly proportional to the number of
reinterventions, being highest (65% and 71%, respectively)
to the outflow target vessel(s) for all-autogenous vein
e-knee popliteal; B, below-knee popliteal; C, tibial or
vals in which fewer than 10 grafts remained eligible forrding
abov
interafter three or more graft revisions.
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This study reconfirms several aspects of infrainguinal
bypass that already are well recognized, such as the unfa-
vorable influence of insulin-dependent diabetes, renal in-
sufficiency, and critical preoperative limb ischemia on pa-
tient survival and limb salvage,21-23 as well as the superior
patency rates of all-autogenous vein grafts compared with
synthetic material. The latter are illustrated in Fig 4, using
data from a collective review by Dalman and Taylor1 and
from meta-analyses that have been conducted more re-
cently by Albers, Pereira and their associates.2,3 Great sa-
phenous vein grafts appear to have better primary patency
rates than synthetic grafts at every outflow level, and this
advantage becomes apparent even at early stages of fol-
low-up after crural revascularization. Others have found
that composite grafts offer no clear advantage over entirely
synthetic grafts,24 and a large randomized clinical trial
(RCT) in Europe has concluded that formal oral anticoag-
ulation does not enhance the durability of synthetic grafts
compared with standard aspirin therapy.25 Consequently,
the fact that some reports have noted a discordantly high
limb salvage rate despite a much lower graft patency rate
represents perhaps the only incentive to recommend syn-
thetic infrapopliteal bypass when alternative veins are un-
Fig 3. Kaplan-Meier estimates of limb salvage after 5
according to the four significant risk factors on multivaria
creatinine; and D, graft material. (Dotted lines indicate
follow-up.)available.26Other issues regarding patient selection and manage-
ment that were raised in the introductory paragraph of this
report now may be discussed in the context of the previous
literature.
Above-knee synthetic grafts. Synthetic conduits
commonly have been used for infrainguinal bypass grafting
to the popliteal artery above the knee on the premise that
perations performed for critical preoperative ischemia
alysis:A, preoperative symptoms; B, diabetes;C, serum
vals in which fewer than 10 limbs remained eligible for
Fig 4. Representative data points from previous collective reviews
and/ormeta-analyses indicating 1-year, 3-year, and 5-year primary
patency rates for above-knee popliteal (black), below-knee popli-
teal (green), and crural (red) infrainguinal bypass grafts con-
structed with great saphenous vein (), arm vein (‘), or PTFE
().1-353 o
ble an
intertheir patency would not be compromised by joint flexion,
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vein for future below-knee bypass if it ever were necessary.
A seminal RCT conducted by Veith et al27 first suggested
that patency rates favored vein grafts even above the knee,
but the trend became apparent only after 2 years of surveil-
lance and was not statistically significant (P  .25). Two
subsequent RCTs with longer lengths of follow-up have
validated this conclusion, however. Johnson et al28 re-
ported that the 5-year primary patency rate for autogenous
vein grafts (73%) was superior to those for either human
umbilical vein (53%) or PTFE (39%) grafts, and Klingert et
al29 described a similar advantage in 5-year patency for
autogenous vein grafts compared with PTFE grafts (76% vs
57%) despite initially finding that their 2-year patency rates
were not significantly different.
Results from the present study reflect both the benefit
and the liability of synthetic grafts for above-knee bypass.
Their 5-year primary patency rate of 66% seems acceptable,
especially in conjunction with a secondary patency rate of
83%. Nevertheless, although too few all-autogenous grafts
(n  15) were done for adequate statistical analysis, their
5-year primary patency rate of 81% conceivably may have
been better than synthetic grafts. Moreover, only five of the
91 synthetic grafts ever were replaced with below-knee
saphenous vein grafts. Considering all of this information,
the senior author currently would employ more vein grafts
above the knee than actually were used in this series.
Bypass for claudication. Ninety-seven procedures
(15%) in the present study were done for claudication
alone, with a single postoperative death and 5-year survival,
primary patency, and major amputation rates of 78%, 62%
and 4.1%, respectively. Nine (19%) of the 47 all-autoge-
nous infrageniculate grafts that were constructed strictly for
claudication ultimately occluded. The Albany group has
reported a much larger series of 409 operations for claudi-
cation, which still comprised only 9.1% of a total of 4468
infrainguinal bypass grafts during the decade from 1987 to
1997 and was associated with no operative deaths, just one
early amputation (0.25%), and 5-year survival and primary
patency rates of 86% and 63%, respectively.30 All but four of
the 244 infrageniculate procedures in the Albany series
were performed using autogenous vein, with 5-year pri-
mary patency rates of 70% for popliteal bypass and 79% for
tibial bypass. The definition of what constitutes truly dis-
abling claudication often is subjective, but these data indi-
cate that infrainguinal revascularization can be a safe and
durable option for carefully selected patients, particularly
when it is done with autogenous grafts.
Age and gender. Older age had its customary unfa-
vorable effect on late survival in the present series, whereas
younger age was associated with a lower primary patency
rate and, in those who were especially young (ie, less than
50 years of age), with a higher risk for major amputation at
the conclusion of the study period. It is difficult to know
whether the higher risks for graft occlusion and limb loss in
younger patients were related to their longer survival and
follow-up periods or instead to a more virulent form of
atherosclerosis than was present in older patients. Genderwas not a significant factor with respect to any outcome on
univariable or multivariable analysis even though women
generally were older than men at the time of their initial
operations. Older age also has been noted for women in
other large series in which female gender likewise did not
influence the success of infrainguinal bypass.31,32 Lower
3-year patency rates33 and a higher incidence of amputation
after early secondary procedures34 occasionally have been
reported for women, but female gender does not seem
sufficiently predictive of poor results to prejudice patient
selection under most circumstances.
Early postoperative thrombosis. Forty-six patients
in the present series were discharged from their index
hospital admissions with patent grafts after early reinterven-
tion for postoperative thrombosis, but the secondary pa-
tency rates for these grafts was just 62% at 1 year and 26% at
5 years of follow-up. Robinson et al35 also encountered a
5-year patency rate of only 23% for 112 primary grafts that
required revision for thrombosis within 30 days, and Belkin
et al9 reported a similar 4-year patency rate of 27% for
autogenous replacement of previous grafts that had oc-
cluded within 3 months of their construction. Lombardi et
al36 had a slightly higher 5-year patency rate of 45% after 33
reoperations for early thrombosis and recommend the use
of an entirely new conduit, even if it means replacing a vein
graft with a synthetic graft, unless a focal underlying lesion
can be identified in the original graft. Whatever surgical
approach is taken in this situation, most patients probably
should be investigated for hypercoagulable disorders and
kept under close surveillance by noninvasive testing simply
because a failed graft still remains in jeopardy once patency
has been restored.
Multiple previous failures. Darling et al11 found that
approximately 10% of 3944 infrainguinal vein grafts even-
tually required revision, and that revised grafts then had a
significantly lower 5-year patency rate (67%) than grafts for
which reintervention never had been necessary (78%). Bel-
kin et al9 employed venous replacement grafts in 75% and
synthetic grafts in 25% of their series of 300 reoperative
procedures, with secondary 5-year patency rates of 52% and
27%, respectively (P .001). Given the potentially limited
success of revised or replaced grafts and the finite availabil-
ity of autogenous conduits, the question of when to con-
sider elective amputation rather than further attempts at
limb salvage inevitably must be addressed in patients who
already have experienced multiple graft failures. De Frang
et al8 have reported remarkable 4-year patency (80%) and
limb salvage (70%) rates after revision or replacement of 85
occluded grafts in patients who had a history of two or
more previous graft failures. These results may not be
universally attainable, since the risks for another graft oc-
clusion or major amputation were directly proportional to
the number of graft revisions in the present study and were
65% and 71%, respectively, after three or more reopera-
tions. Important decisions regarding the possible futility of
additional bypass efforts must be tailored to individual
cases, but patients who find themselves in this dilemma
should at least consider the choice of permanent rehabili-
JOURNAL OF VASCULAR SURGERY
August 2007278 Hertzer et altation to a prosthetic limb if their ischemic symptoms are
intolerable.
CONCLUSIONS
According to the results of the present study, diabetes is
merely one of several factors influencing survival and limb
loss. Diabetes has no measurable effect on graft patency,
and a certain number of insulin-dependent diabetics will
require major amputation because of irreversible distal isch-
emia even in the presence of patent grafts. All-autogenous
grafts clearly are superior to synthetic grafts below the knee
and may also be preferable above the knee. Early postoper-
ative graft occlusions are more likely to occur after second-
ary infrainguinal procedures and are associated with com-
paratively low late patency rates even if these grafts initially
are salvaged by immediate reoperations. Younger patients
have a higher risk for late graft failure, and the number of
graft revisions is an important predictor of further occlusion
or amputation.
John J. Smetanko, Cleveland Clinic Health Data Ser-
vices, and his staff provided the medical records that were
reviewed for all patients in this study.
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All operations NA 650 31 4.8 NA NA NA
Diabetes No* 338 10 3.0 1.0 .029
Yes 312 21 6.7 2.4 (1.1, 5.1)
Diabetic classification No diabetes* 338 10 3.0 1.0 .082
Noninsulin-
dependent
117 7 3.6 2.1 (0.77, 5.7) .15
Insulin-dependent 195 14 7.2 2.5 (1.1, 5.8) .029
Gender Men 412 15 3.6 1.0 .080
Women 238 16 6.7 1.9 (0.92, 3.9)
Age (y) 59 or younger 168 7 4.2 1.0 .32
60 to 69 229 8 3.5 0.83 (0.30, 2.3) .73
70 or older 253 16 6.3 1.6 (0.62, 3.9) .34
10-y increments 1.3 (0.83, 1.9) .27
Preoperative symptoms Claudication only 97 1 1.0 1.0 .096
Critical ischemia 553 30 5.4 5.5 (0.74, 40)
Serum creatinine (mg/dL)† 1.5 or lower 511 15 2.9 1.0 .001
1.6 to 1.9 68 4 5.9 2.1 (0.66, 6.4) .21
2.0 or higher 31 6 19 7.9 (2.8, 22) .001
Dialysis 28 6 21 9.0 (3.4, 24) .001
Log-transformed serum creatinine (doubling) 3.7 (2.1, 6.7) .001
Prior CABG or PTCA No 508 25 4.9 1.0 .74
Yes 142 6 4.2 0.85 (0.34, 2.1)
Severe clinical COPD No 630 29 4.6 1.0 .28
Yes 20 2 10 2.3 (0.50, 11)
Graft material All-autogenous
vein
389 21 5.4 1.0 .36
Synthetic or
composite
261 10 3.8 0.70 (0.32, 1.5)




75 4 5.3 1.1 (0.39, 3.4)
Outflow target vessel(s) Above-knee
popliteal
106 1 0.9 1.0 .064
Below-knee
popliteal
199 16 8.0 9.2 (1.2, 70) .033
Tibial or peroneal 304 13 4.3 4.7 (0.61, 36) .14
Multiple vessels 41 1 2.4 2.6 (0.16, 43) .50
Previous ipsilateral
infrainguinal bypass
No 531 30 5.6 1.0 .055
Yes 119 1 0.8 0.14 (0.02, 1.0)
Year of operation 1976-1980 102 7 6.9 1.0 .85
1981-1985 174 7 4.0 0.57 (0.19, 1.7) .30
1986-1990 122 5 4.1 0.58 (0.18, 1.9) .36
1991-1995 117 6 5.1 0.73 (0.24, 2.3) .59
1996-2002 135 6 4.4 0.63 (0.20, 2.0) .42
NA, Not applicable; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; COPD, chronic obstructive pulmonary
disease.
*Includes 12 operations in 11 patients whose diabetic status is unknown.
†Excludes 12 operations in 10 patients because of unavailable preoperative data.
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Category n





1 year (%) 5 years (%) 10 years (%) 15 years (%)
Versus
reference Overall
All patients* NA 565 84 (80, 87) 52 (48, 56) 25 (21, 30) 11 (7.7, 14) NA NA NA
Diabetes No† 299 86 (82, 90) 59 (53, 65) 35 (29, 42) 16 (11, 21) 1.0 .001
Yes 266 80 (76, 85) 44 (38, 51) 15 (10, 20) 5.8 (2.2, 9.3) 1.6 (1.3, 1.9)
Diabetic
classification
No diabetes† 299 86 (82, 90) 59 (53, 65) 35 (29, 42) 16 (11, 21) 1.0 .001
Noninsulin-
dependent
165 81 (73, 89) 43 (33, 53) 14 (6.7, 22) 8.1 (1.8, 14) 1.5 (1.2, 2.0) .001
Insulin-dependent 101 80 (74, 86) 45 (37, 53) 16 (9.7, 22) 4.2 (0.1, 8.3) 1.6 (1.3, 2.0) .001
Gender Men 358 82 (78, 86) 53 (48, 59) 26 (20, 31) 12 (8.0, 16) 1.0 .39
Women 207 85 (80, 90) 50 (43, 58) 25 (18, 32) 8.7 (3.8, 14) 1.1 (0.90, 1.3)
Age (y) 59 or younger 144 87 (82, 93) 65 (56, 73) 46 (36, 55) 24 (15, 33) 1.0 .001
60 to 69 200 88 (84, 93) 61 (54, 68) 29 (22, 36) 12 (6.7, 17) 1.4 (1.1, 1.8) .015
70 or older 221 77 (72, 84) 37 (30, 43) 9.5 (4.9, 14) 1.1 (0.0, 3.1) 2.5 (2.0, 3.3) .001
10-y increments 1.5 (1.3, 1.6) .001
Preoperative
symptoms
Claudication only 78 93 (88, 99) 78 (68, 88) 47 (34, 60) 29 (16, 42) 1.0 .001
Critical ischemia 487 82 (78, 85) 48 (44, 53) 22 (18, 26) 8.4 (5.4, 11) 2.3 (1.7, 3.2)
Serum creatinine
(mg/dL)‡
1.5 or lower 443 88 (84, 91) 58 (54, 63) 31 (26, 36) 14 (9.5, 18) 1.0 .001
1.6 to 1.9 58 81 (71, 91) 43 (30, 56) 14 (4.0, 23) 4.6 (0.0, 11) 1.6 (1.2, 2.1) .002
2.0 or higher 29 50 (32, 69) 25 (8.5, 41) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 3.6 (2.4, 5.4) .001
Dialysis 25 59 (39, 78) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 5.6 (3.5, 8.7) .001
Log-transformed serum creatinine (doubling) 1.8 (1.5, 2.2) .001
Prior CABG or
PTCA
No 444 84 (80, 87) 54 (49, 58) 27 (22, 32) 12 (8.1, 16) 1.0 .23
Yes 121 82 (75, 89) 47 (37, 56) 20 (12, 28) 7.5 (1.5, 14) 1.2 (0.92, 1.4)
Severe clinical
COPD
No 548 84 (81, 87) 53 (49, 58) 26 (22, 30) 11 (7.9, 14) 1.0 .001
Yes 17 63 (40, 87) 18 (0.0, 39) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 2.6 (1.5, 4.5)
Graft material All-autogenous
vein
343 84 (80, 88) 52 (46, 57) 26 (20, 31) 10 (5.9, 14) 1.0 .71
Synthetic or
composite
222 82 (77, 88) 53 (46, 60) 25 (19, 32) 12 (6.9, 17) 1.0 (0.86, 1.3)
Inflow source
vessel










95 83 (75, 90) 51 (40, 62) 20 (11, 29) 9.6 (2.6, 17) 1.0 .42
Below-knee
popliteal
179 83 (77, 89) 56 (48, 63) 29 (21, 36) 14 (7.3, 20) 0.79 (0.59, 1.0) .099
Tibial or peroneal 261 85 (80, 89) 51 (44, 57) 25 (19, 31) 9.7 (5.0, 14) 0.88 (0.67, 1.1) .34





No 455 81 (78, 85) 47 (42, 52) 20 (16, 24) 9.0 (5.8, 12) 1.0 .001
Yes 110 94 (89, 98) 73 (64, 82) 50 (39, 61) 20 (9.6, 30) 0.54 (0.42, 0.71)
Year of operation 1976-1980 96 82 (75, 90) 61 (51, 71) 30 (20, 40) 18 (9.4, 26) 1.0 .033
1981-1985 154 86 (80, 91) 55 (46, 63) 26 (18, 33) 8.7 (3.9, 13) 1.3 (0.97, 1.7) .085
1986-1990 104 86 (79, 92) 52 (43, 62) 32 (23, 42) 12 (5.5, 20) 1.1 (0.80, 1.5) .58
1991-1995 94 76 (68, 85) 42 (32, 53) 17 (7.9, 27) NA 1.6 (1.2, 2.2) .006
1996-2002 117 86 (79, 92) 44 (33, 56) NA NA 1.5 (1.0, 2.1) .027
NA, Not applicable; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; COPD, chronic obstructive pulmonary
disease.
*Status at time of first procedure in patients receiving bilateral operations.
†Includes 11 patients whose diabetic status is unknown.
‡Excludes 10 patients because of unavailable preoperative data.
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1 year (%) 5 years (%) 10 years (%) 15 years (%)
Versus
Reference Overall
All patients NA 650 67 (63, 71) 52 (47, 57) 37 (30, 44) 32 (25, 40) NA NA NA
Diabetes No* 338 64 (59, 70) 46 (40, 52) 34 (26, 43) 28 (18, 37) 1.0 .049
Yes 312 70 (65, 76) 59 (52, 66) 41 (29, 52) 41 (29, 52) 0.78 (0.60, 1.0)
Diabetic
classification
No diabetes* 338 64 (59, 70) 46 (40, 52) 34 (26, 43) 28 (18, 37) 1.0 .080
Noninsulin-
dependent
117 71 (62, 80) 63 (53, 74) 52 (38, 66) 52 (38, 66) 0.67 (0.47, 0.96) .031
Insulin-dependent 195 69 (62, 76) 57 (48, 65) 34 (18,49) 34 (18, 49) 0.84 (0.63, 1.1) .25
Gender Men 412 68 (63, 73) 53 (47, 58) 39 (30, 48) 39 (30, 48) 1.0 .22
Women 238 65 (58, 71) 51 (43, 58) 32 (20, 44) 22 (8.8, 34) 1.2 (0.91, 1.5)
Age (y) 59 or younger 168 57 (49, 65) 40 (30, 49) 21 (9.5, 33) 21 (9.5, 33) 1.0 .002
60 to 69 229 69 (63, 75) 52 (44, 59) 39 (30, 49) 35 (25, 45) 0.72 (0.54, 0.97) .028
70 or older 253 72 (66, 78) 62 (54, 70) 38 (6.6, 69) NA 0.57 (0.42, 0.79) .001
10-y increments 0.84 (0.75, 0.94) .003
Preoperative
symptoms
Claudication only 97 80 (72, 88) 62 (52, 73) 41 (25, 57) 41 (25, 57) 1.0 .032
Critical ischemia 553 64 (60, 69) 50 (44, 55) 37 (29, 44) 32 (23, 40) 1.5( 1.0, 2.1)
Serum creatinine
(mg/dL)†
1.5 or lower 511 66 (62, 71) 52 (46, 57) 38 (30, 45) 33 (25, 41) 1.0 .64
1.6 to 1.9 68 66 (53, 78) 45 (30, 60) 26 (7.0, 44) 26 (7.0, 44) 1.1 (0.76, 1.6) .58
2.0 or higher 31 73 (54, 92) 67 (46, 88) NA NA 0.65 (0.31, 1.4) .27
Dialysis 28 63 (41, 86) NA NA NA 0.90 (0.42, 1.9) .79
Log-transformed serum creatinine (doubling) 0.95 (0.76, 1.2) .67
Prior CABG or
PTCA
No 508 64 (60, 69) 50 (45, 55) 34 (25, 42) 34 (25, 42) 1.0 .045
Yes 142 77 (69, 84) 59 (49, 69) 46 (32, 60) 31 (14, 48) 0.73 (0.53, 0.99)
Severe clinical
COPD
No 630 66 (62, 70) 51 (46, 56) 37 (30, 44) 32 (25, 40) 1.0 .040
Yes 20 88 (73, 100) 88 (73, 100) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.35 (0.13, 0.95)
Graft material All-autogenous
vein
389 69 (64, 74) 57 (52, 63) 44 (35, 53) 42 (32, 51) 1.0 .003
Synthetic or
composite
261 64 (58, 70) 44 (36, 51) 27 (17, 37) 18 (6.4, 30) 1.4 (1.1, 1.8)
Inflow source
vessel










106 82 (74, 90) 68 (57, 79) 40 (20, 61) NA 1.0 .010
Below-knee
popliteal
199 62 (54, 69) 45 (37, 54) 33 (21, 46) 27 (11, 42) 1.9 (1.3, 2.8) .001
Tibial or peroneal 304 66 (60, 71) 52 (45, 59) 38 (29, 48) 36 (26, 46) 1.6 (1.1, 2.3) .020





No 531 72 (68, 76) 57 (52, 62) 39 (30, 48) 33 (23, 43) 1.0 .001
Yes 119 46 (37, 56) 32 (22, 42) 25 (14, 37) 25 (14, 37) 1.9 (1.4, 2.5)
Year of operation 1976-1980 102 53 (43, 63) 41 (30, 51) 28 (13, 42) 28 (13, 42) 1.0 .021
1981-1985 174 71 (64, 78) 49 (40, 58) 36 (24, 48) 26 (14, 39) 0.70 (0.48, 1.0) .051
1986-1990 122 72 (63, 80) 62 (52, 72) 49 (35, 63) 49 (36, 63) 0.51 (0.33, 0.78) .002
1991-1995 117 66 (57, 75) 51 (40, 61) 26 (8.3, 44) NA 0.74 (0.51, 1.1) .14
1996-2002 135 69 (60, 77) 55 (44, 67) NA NA 0.58 (0.39, 0.88) .011
NA, Not applicable; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; COPD, chronic obstructive pulmonary
disease.
*Includes 12 operations in 11 patients whose diabetic status is unknown.
†Excludes 12 operations in 10 patients because of unavailable preoperative data.
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Category n





1 year (%) 5 years (%) 10 years (%) 15 years (%)
Versus
reference Overall
All patients NA 650 81 (78, 84) 75 (71, 78) 60 (53, 68) 57 (50, 65) NA NA NA
Diabetes No* 338 84 (79, 88) 76 (71, 82) 66 (58, 75) 62 (51, 72) 1.0 .050
Yes 312 78 (74, 83) 73 (67, 78) 51 (38, 64) 51 (38, 64) 1.4 (1.0, 1.9)
Diabetic
classification
No diabetes* 338 84 (79, 88) 76 (71, 82) 66 (58, 75) 62 (51, 72) 1.0 .001
Noninsulin-
dependent
117 85 (78, 92) 84 (77, 91) 69 (52, 87) 69 (52, 87) 0.83 (0.50, 1.4) .47
Insulin-dependent 195 74 (68, 81) 66 (58, 74) 40 (22, 58) 40 (22, 58) 1.8 (1.3, 2.5) .001
Gender Men 412 83 (79, 87) 77 (73, 82) 63 (54, 72) 60 (50, 70) 1.0 .13
Women 238 78 (72, 83) 70 (63, 77) 56 (45, 68) 53 (41, 66) 1.3 (0.93, 1.8)
Age (y) 59 or younger 168 76 (69, 83) 72 (64, 79) 50 (36, 65) 46 (31, 62) 1.0 .22
60 to 69 229 83 (78, 88) 73 (67, 80) 62 (53, 72) 62 (53, 72) 0.79 (0.54, 1.2) .23
70 or older 253 83 (78, 88) 79 (72, 85) 70 (58, 83) NA 0.70 (0.46, 1.0) .087
10-y increments 0.85 (0.70, 1.0) .95
Preoperative
symptoms
Claudication only 97 99 (96, 100) 96 (91, 100) 80 (63, 97) 80 (63, 97) 1.0 .001
Critical ischemia 553 78 (74, 82) 70 (66, 75) 56 (48, 64) 53 (44, 61) 6.1 (2.8, 13)
Serum creatinine
(mg/dL)†
1.5 or lower 511 81 (77, 84) 74 (70, 78) 59 (52, 67) 56 (48, 64) 1.0 .001
1.6 to 1.9 68 87 (79, 96) 87 (79, 96) 87 (79, 96) 87 (79, 96) 0.50 (0.24, 1.0) .062
2.0 or higher 31 94 (85, 100) 86 (71, 100) NA NA 0.52 (0.17, 1.6) .26
Dialysis 28 56 (35, 78) NA NA NA 2.7 (1.6, 4.7) .001
Log-transformed serum creatinine (doubling) 0.70 (0.49, 1.0) .048
Prior CABG or
PTCA
No 508 80 (76, 83) 72 (68, 77) 57 (48, 65) 55 (46, 64) 1.0 .050
Yes 142 87 (81, 93) 82 (75, 89) 72 (60, 85) 65 (48, 83) 0.64 (0.41, 1.0)
Severe clinical
COPD
No 630 81 (78, 84) 74 (70, 78) 60 (53, 67) 57 (49, 65) 1.0 .30
Yes 20 89 (76, 100) 89 (76, 100) NA NA 0.49 (0.13, 1.9)
Graft material All-autogenous
vein
389 83 (79, 87) 77 (72, 82) 64 (55, 74) 59 (48, 70) 1.0 .17
Synthetic or
composite
261 79 (73, 84) 71 (64, 77) 55 (43, 66) 55 (43, 66) 1.2 (0.91, 1.7)
Inflow source
vessel










106 90 (82, 96) 86 (78, 93) 59 (36, 82) 59 (36, 82) 1.0 .092
Below-knee
popliteal
199 81 (76, 87) 73 (66, 81) 70 (61, 78) 70 (61, 78) 1.5 (0.85, 2.7) .16
Tibial or peroneal 304 78 (73, 83) 72 (66, 78) 59 (49, 68) 52 (39, 64) 2.0 (1.1, 3.4) .016




No 531 83 (80, 86) 76 (72, 80) 62 (53, 70) 57 (48, 67) 1.0 .089
Yes 119 73 (64, 81) 68 (59, 77) 55 (41, 69) 55 (41, 69) 1.4 (0.95, 2.0)
Year of operation 1976-1980 102 71 (62, 81) 65 (54, 75) 54 (38, 69) 48 (30, 65) 1.0 .25
1981-1985 174 82 (76, 88) 74 (67, 82) 68 (59, 78) 64 (52, 76) 0.64 (0.41, 1.0) .061
1986-1990 122 84 (78, 91) 78 (70, 87) 54 (38, 70) 54 (38, 70) 0.63 (0.39, 1.0) .065
1991-1995 117 83 (76, 90) 76 (67, 86) 60 (41, 79) NA 0.63 (0.38, 1.1) .082
1996-2002 135 83 (77, 90) 78 (71, 86) NA NA 0.62 (0.37, 1.0) .078
NA, Not applicable; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; COPD, chronic obstructive pulmonary
disease.
*Includes 12 limbs in 11 patients whose diabetic status is unknown.
†Excludes 12 limbs in 10 patients because of unavailable preoperative data.
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P valueNo. % No. %
Operations 312 48 338 52
Insulin-dependent diabetes 195 62 NA NA
Men 195 62 217 64 .65
Women 117 38 121 36
Age (y) .62
59 or younger 85 27 83 25
60 to 69 111 36 118 35
70 or older 116 37 137 40
Preoperative symptoms
Claudication only 27 8.7 70 21 .001
Rest pain 92 29 140 41 .002
Cutaneous ulceration 81 26 71 21 .14
Gangrene 108 35 45 13 .001
Distal emboli 4 1.3 12 3.6 .062
Overall classification .001
Claudication only 27 8.7 70 21
Critical ischemia 285 91 268 79
Serum creatinine (mg/dL) .003
1.5 or lower 225 72 286 85
1.6 to 1.9 42 13 26 7.7
2.0 or higher 20 6.4 11 3.3
Dialysis 21 6.7 7 2.1
Data unavailable 4 1.3 8 2.4
Prior CABG or PTCA 81 26 61 18 .015
Incidental 79 25 49 14 .001
Planned preliminary 2 0.6 12 3.6
Severe clinical COPD 8 2.6 12 3.6 .47
Previous ipsilateral procedures 106 34 160 47 .001
Inflow operations 25 8.0 65 19 .001
Infrainguinal bypass 39 12 80 24 .001
Femoral endarterectomy or
profundaplasty
6 1.9 16 4.7 .048
Lumbar sympathectomy 13 4.2 11 3.3 .54
Balloon angioplasty 9 2.9 5 1.5 .22
Minor amputations or
other
17 5.4 4 1.2 .002
Major contralateral
amputation
35 11 26 7.7 .12
Below-knee 23 7.4 13 3.8 .22
Above-knee 12 3.8 13 3.8
NA, Not applicable; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; COPD, chronic obstructive pulmonary
disease.
*Includes 12 operations in 11 patients whose diabetic status is unknown.
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Autogenous grafts 389 17 116 29 62 78 79 27
In situ saphenous
vein
163 3 40 14 24 39 35 16
Reversed
saphenous vein
165 14 65 11 28 29 19 7
Nonreversed
saphenous vein
13 0 0 0 1 2 7 3
Arm vein 34 0 7 4 5 8 11 1
Spliced vein 14 0 4 0 4 0 7 0
Synthetic grafts 261 98 101 16 27 20 21 1
Ringed PTFE 78 28 26 6 11 4 5 0
Nonringed PTFE 139 64 57 6 5 7 5 0
Composite
PTFE/vein
39 5 16 3 10 9 11 1
Other 5 1 2 1 1 0 0 0
Total 650* 115 217 45 89 98 100 28
AK, Above-knee; BK, below-knee; PTFE, polytetrafluorethylene.
*Includes 41 grafts with multiple (n  83) outflow target vessels.
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1.8 (0.65, 5.2) .25







1.6 to 1.9 2.1 (0.65, 6.5) .22
2.0 or higher 8.1 (2.8, 24) .001










9.2 (1.2, 72) .035
Tibial or peroneal 4.2 (0.53, 34) .17
Multiple vessels 2.0 (0.12, 35) .63
*Model also considered gender, age, preoperative symptoms









0.48 (0.22, 1.0) .067




No (reference set) 1.0





No (reference set) 1.0
Yes 2.4 (1.4, 4.1)









0.96 (0.37, 2.5) .93




No (reference set) 1.0
Yes 0.35 (0.13, 0.90)
CABG, Coronary artery bypass grafting; PTCA, percutaneous transluminal
coronary angioplasty.
‡Model also considered age and outflow target vessel(s).Table IV. Multivariable associations with late death, loss













1.4 (1.1, 1.8) .015





60 to 69 1.3 (1.0, 1.8) .033














1.6 to 1.9 1.6 (1.2, 2.1) .004
2.0 or higher 2.7 (1.8, 4.1) .001
Dialysis 4.2 (2.7, 6.6) .001
Severe clinical COPD .026
No (reference set) 1.0





No (reference set) 1.0
Yes 0.67 (0.51, 0.89)









0.69 (0.48, 0.99) .046





60 to 69 0.78 (0.59, 1.0) .093














Below-knee popliteal 2.0 (1.3, 3.0) .003
Tibial or peroneal 2.0 (1.3, 3.1) .002
Multiple vessels 2.0 (1.1, 3.6) .023
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No (reference set) 1.0
Yes 1.6 (1.2, 2.1)




1981 to 1985 0.72 (0.51, 1.0) .067
1986 to 1990 0.58 (0.38, 0.87) .009
1991 to 1995 0.85 (0.58, 1.2) .41
1996 to 2002 0.59 (0.39, 0.89) .012
†Model also included preoperative symptoms (claudication only









0.80 (0.49, 1.3) .38














1.6 to 1.9 0.51 (0.25, 1.0) .067
2.0 or higher 0.51 (0.16, 0.25) .25








COPD, Chronic obstructive pulmonary disease; CABG, coronary artery
bypass grafting; PTCA, percutaneous transluminal coronary angioplasty.
‡Model also considered year of operation.
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Outflow level Type of vein graft n
Kaplan-Meier patency estimates Hazard ratio for
occlusion (95%
CI) P value1 year (%) 5 years (%) 10 years (%) 15 years (%)








13 90  20 79  17 79  17 NA 0.30 (0.08, 1.2) .088
In situ GSV 153 74  7 69  8 50  16 42  20 0.65 (0.44, 0.96) .029
Arm vein 32 60  17 30  20 30  20 30  20 1.3 (0.82, 2.1) .27
Spliced vein 13 50  19 50  19 NA NA 1.5 (0.55, 3.9) .44
Popliteal Reversed GSV 62 67  12 58  13 52  16 52  16 1.0 .84
In situ GSV 40 64  15 64  15 NA NA 0.94 (0.49, 1.8)
Crural Reversed GSV 83 64  12 45  14 28  17 28  17 1.0 .011











13 100  0 100  0 100  0 NA 0.00 (0.00, 0.00) .001
In situ GSV 153 83  6 80  7 59  17 51  21 0.55 (0.36, 0.85) .007
Arm vein 32 70  17 54  20 54  20 54  20 0.99 (0.55, 1.8) .97
Spliced vein 13 50  19 50  19 NA NA 1.6 (0.67, 4.0) .28
Popliteal Reversed GSV 62 69  12 62  15 55  17 55  17 1.0 .49
In situ GSV 40 73  15 73  15 NA NA 0.78 (0.38, 1.6)
Crural Reversed GSV 83 74  10 60  13 35  21 35  21 1.0 .007











13 100  0 100  0 100  0 NA 0.00 (0.00, 0.00) .001
In situ GSV 153 92  5 86  7 64  18 56  22 0.39 (0.24, 0.64) .001
Arm vein 32 77  15 66  20 66  20 66  20 0.77 (0.37, 1.6) .48
Spliced vein 13 46  30 46  30 NA NA 1.9 (0.74, 4.9) .18
Popliteal Reversed GSV 62 73  12 66  14 66  14 66  14 1.0 .16
In situ GSV 40 88  11 78  16 58  25 58  25 0.55 (0.24, 1.3)
Crural Reversed GSV 83 76  10 61  13 38  20 38  20 1.0 .001
In situ GSV 113 93  5 88  7 66  11 56  24 0.34 (0.18, 0.62)GSV, Great saphenous vein.
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revascularization at the end of the entire study period
n
Occluded graft Major amputation
n % P value* n % P value*
Total 650 176 27 NA 154 24 NA
Gender .083 .061
Men 412 101 25 88 21
Women 238 75 32 66 28
Age (y) .27 .008
50 or
younger
56 16 29 17 30
51 to 64 235 79 34 73 31
65 to 74 224 54 24 38 17




No diabetes† 338 104 31 73 22
Noninsulin-
dependent
117 24 21 20 17
Insulin-
dependent






97 22 23 6 6.2
Critical
ischemia





No 531 121 23 115 22









46 20 43 15 33
Graft revisions .001 .001
None 465 98 21 85 18
1 126 44 35 36 29
2 42 23 55 21 50
3 or more 17 11 65 12 71
NA, Not applicable.
*Generalized estimating equation model.
†Includes 12 operations in 11 patients whose diabetic status is unknown.
